SCHEDULE: RA Capital's Sionna Therapeutics Stake Diluted to 22.6%

RA Capital Management and its affiliates report a dilution of their beneficial ownership in Sionna Therapeutics, Inc. to 22.6% of common stock outstanding.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P., and RA Capital Nexus Fund III, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13D.
• The amendment reports a dilution of the Reporting Persons' beneficial ownership in Sionna Therapeutics, Inc. common stock.
• The Reporting Persons collectively beneficially own 10,071,712 shares of Common Stock, representing 22.6% of the Issuer's outstanding shares.
• This percentage is based on 44,628,788 shares of Common Stock outstanding as of October 31, 2025, as reported by Sionna Therapeutics, Inc. in its Quarterly Report on Form 10-Q.
• The filing states the amendment is not a result of any acquisition or disposition of securities by the Reporting Persons, but rather to report dilution.
• However, the filing also discloses open market sales by the Reporting Persons totaling 373,610 shares between October 24, 2025, and October 28, 2025, at weighted average prices ranging from $39.50 to $39.58 per share.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the reported dilution of a significant investor's stake and the disclosure of open market sales by that investor. While the filing states the amendment is due to dilution (implying issuer action), the investor's own sales contribute to a reduced position.

Negatives

• The beneficial ownership percentage of RA Capital and its affiliates in Sionna Therapeutics, Inc. has been diluted to 22.6%.
• RA Capital and its affiliates conducted open market sales of 373,610 shares of Sionna Therapeutics common stock in late October 2025.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Sionna Therapeutics, Inc. or the Reporting Persons' future investment intentions beyond the reported ownership changes.

Industry Context

This filing reflects a change in a significant institutional investor's stake in a biotechnology company. While the filing attributes the amendment to dilution, the concurrent open market sales by RA Capital could be interpreted by the market as a strategic adjustment to their position, potentially influenced by the company's performance, market conditions, or portfolio rebalancing within the biotech sector.

Stakeholder Impact

• Shareholders: The dilution of a major institutional investor's stake, coupled with their recent sales, could be perceived negatively by other shareholders, potentially signaling a reduced conviction or a strategic rebalancing by RA Capital. This could lead to increased scrutiny of the company's recent performance or future prospects.
• Company Management: The company's management may face questions regarding the reasons for the dilution (e.g., recent capital raises) and the implications of a reduced stake by a prominent investor.

Key Dates

Keywords

Sionna Therapeutics, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Dilution, Common Stock, Institutional Investor, Healthcare Fund, Biotechnology